Neoadjuvant Chemoradiation for Rectal Cancer

Introduction to Neoadjuvant Therapy

• The National Comprehensive Cancer Network (NCCN) recommends neoadjuvant chemoradiation with fluoropyrimidine (5-FU or capecitabine) for patients with stage II/III rectal cancer, followed by surgery and adjuvant chemotherapy 1.

Role of Concurrent Chemoradiation

• Concurrent chemoradiation is the standard treatment for stage II/III rectal cancer, with benefits including increased pathological complete response (pCR) rates (11.4% vs 3.6%, P<0.05) and reduced local recurrence (8.1% vs 16.5%, P<0.05) 1.
• The American College of Radiology and the NCCN suggest that concurrent chemoradiation improves anal sphincter preservation and early control of micrometastases 1.

Recommended Chemotherapy Regimens

• Capecitabine is a preferred option due to its convenience and equivalent efficacy to continuous infusion 5-FU 2.
• 5-FU with leucovorin is an alternative, although it has a higher risk of hematologic toxicity 1.

Total Neoadjuvant Therapy (TNT)

• The NCCN suggests TNT for high-risk patients, consisting of prolonged chemoradiation (45-50 Gy with fluoropyrimidine) followed by consolidation chemotherapy with FOLFOX or CAPEOX for 12-16 weeks, and then surgery 3, 4.
• TNT has benefits including increased pCR rates (up to 27.5% with FOLFOX/RT vs 14% with 5-FU/RT) and improved tolerance to chemotherapy when given before surgery 4.

Adjuvant Chemotherapy

• All patients with stage II/III rectal cancer should receive adjuvant chemotherapy after neoadjuvant chemoradiation and surgery, regardless of pathological response 5, 6.
• Recommended regimens include FOLFOX or CAPEOX for high-risk patients and 5-FU/LV or capecitabine for lower-risk patients or those with a good response to fluoropyrimidine 5, 6.

Timing and Coordination of Treatment

• The interval between completion of chemoradiation and surgery should be 7-8 weeks to optimize response 4.
• The total duration of perioperative treatment should not exceed 6 months 7.

Clinical Practice and Barriers to Adjuvant Chemotherapy

• Only 61.5-76.6% of patients receive adjuvant chemotherapy in clinical practice, which is lower than recommended 5, 6.
• Factors associated with not receiving adjuvant chemotherapy include pathological complete response, postoperative complications, older age, poor performance status, and socioeconomic factors 5.

Neoadjuvant Chemotherapy for Stage II/III Rectal Cancer

Standard Neoadjuvant Chemoradiation Regimen

• The National Comprehensive Cancer Network recommends a radiation dose of 45-50 Gy delivered over 25-28 fractions (1.8-2.0 Gy per fraction) 8, 9

Risk-Stratified Treatment Selection

• For low-risk patients, selective neoadjuvant chemotherapy alone with FOLFOX for 5-6 cycles may be considered 8
• For high-risk patients, total neoadjuvant therapy (TNT) is recommended, achieving higher pathological complete response rates (up to 27.5% with FOLFOX/RT versus 14% with 5-FU/RT alone) 10

Short-Course Radiotherapy Option

• For select patients, 25 Gy in 5 fractions may be used for cT3 tumors without sphincter preservation requirements 8, 9

Timing Considerations

• Surgery should occur 5-12 weeks after completing full-dose chemoradiation to allow recovery from toxicity while optimizing pathological response 9

Adjuvant Chemotherapy (Post-Surgery)

• The total perioperative treatment duration should not exceed 6 months 8

Chemotherapy Without Radiation (Emerging Approach)

• For highly selected low/intermediate-risk patients, FOLFOX alone for 5-6 cycles may be considered for mid-upper rectal cancer without sphincter preservation concerns 8
• The FOWARC trial showed FOLFOX without RT achieved lower pathological complete response (6.6%) compared to FOLFOX/RT (27.5%), but acceptable R0 resection rates (90-100%) 10

Special Populations

• For MSI-H/dMMR stage III rectal cancer, the UNION phase III trial demonstrated that sequential short-course radiotherapy, immunotherapy, and chemotherapy significantly improved pathological complete response rates in pMMR/MSS patients 8